

Programme 3rd Freiburg Epigenetic Spring Meeting

10.04.2016 Sunday Opening

(14-17h COST EPICHEM BIO WG1 meeting (only MC members)
18.30 - 19.00 Welcome @ FRIAS (Albertstr. 19)

19.00 Opening Reception at FRIAS FRIAS lounge

11.04.2016 Monday, Day 1 (Albertstr. 21, Chemistry building)

08:45 - 09:00 Organiser's introduction
09.00 - 09.30 Roland Schüle LSD1 controls chromosomal integrity and much more
09.30 - 10.00 Chris Schofield Role of Oxygenases in Epigenetics
10.00 - 10.30 Dirk Schwarzer Peptide-based probes for lysine deacetylases
10.30 - 11.00 Coffee break
11.00 - 11.30 Stefan Günther Inhibiting the bromodomains of CBP and p300 to probe their role in chronic lymphocytic leukemia
11.30 - 12.00 Stuart Conway Targeting Epigenetic Reader Proteins Using Chemical Biology
12.00 - 12.30 Stefan Knapp Towards a comprehensive chemical probe set targeting bromodomains
12.30 - 14.00 Lunch
14.00 - 14.30 Wolfgang Sippl Structure-based design with epigenetic targets - the discovery of novel inhibitors for PRK1 kinase and JumonjiC domain-containing histone demethylases
14.30 - 15.00 Manfred Jung Targeting readers of the epigenetic code - Assays and inhibitors for methyl-histone binding proteins
15.00 - 15.30 Stefan Kubicek Mapping the chemical chromatin reactivation landscape
15.30 - 16.00 Alexander Cote Structure-guided discovery of potent and selective bromodomain inhibitors and their application to phenotype discovery
16.00 - 16.30 Coffee break
16.30 - 17.00 Antonello Mai Development of novel EZH2 inhibitors active in cancer cells
17.00 - 17.30 pending
17.30 - 18.00 Akane Kawamura Development of JmJc histone demethylase inhibitors
18.00 - 19.00 Udo Oppermann (Plenary lecture) Targeting histone demethylases in immuno-oncology
19.00 - 21.30 Poster Sessions with wine and snacks Foyer and Seminar room Albertstr. 21

12.04.2016 Tuesday, Day 2 (Albertstr. 21, Chemistry building)

09.00 - 09.30 Ray Pierce Histone deacetylases as therapeutic targets for neglected parasitic diseases
09.30 - 10.00 Chris Romier Structural basis for specific inhibition of HDAC8 from Schistosoma mansoni
10.00 - 10.30 Rab Prinjha Epigenetic Drug Discovery: From Target to Patients
10.30 - 11.00 Coffee break
11.00 - 11.30 Tim McKinsey Chemical Epigenetic Dissection of Heart Failure
11.30 - 12.00 Ritwick Sawarkar Hsp90 buffers genetic variation via epigenetic mechanisms
12.00 - 12.30 Stephen Shuttleworth Design and Development of a Novel Series of HDAC6-Selective Inhibitors for Hematological Cancer Treatment and Solid Tumor Immunotherapy
12.30 - 13.30 Lunch
13.30 - 14.00 A. Ganesan Erasing the Erasers: Studies with HDAC and LSD1 Inhibitors
14.00 - 14.30 Christian Olsen Macrocyclic Inhibitors of the Human Histone Deacetylase (HDAC) Enzymes
14.30 - 15.00 John Denu Catalytic Activation of the SIRT6 protein deacetylase
15.00 - 15.30 Clemens Steegborn Sirtuins: Molecular mechanisms of substrate selection, inhibition, and activation
15.30 - 16.00 Coffee break

16.00 - 16.30	Gianluca Sbardella	Cell-Permeable modulators of Histone Acetyltransferases for the regulation of behavioral plasticity
16.30 - 17.00	Angel de Lera	Palladium-catalyzed Cascade Reactions for the Synthesis of Paullones, SIRT Modulators
17.00 - 17.30	Paola Arimondo	Chemical tools for DNA methylation targeting in cancer cells
17.30 - 18.00	Harald Engelhardt	Discovery of a Potent BET-Inhibitor by Agile Hit Finding Approaches
18.15 - 19.15	Thomas Carell (Plenary lecture)	Oxidized Cytosine Bases with Novel Epigenetic Functions I
19.45	<i>Speakers dinner</i>	<i>Greiffeneggschlössle</i>

13.04.2016 **Wednesday, Day 3 (Albertstr. 21, Chemistry building)**

09.00 - 09.30	Rasmus Clausen	Development of inhibitors and tools for histone demethylases
09.30 - 10.00	Jun Qi	Targeting on Epigenetic Proteins for Cancer Therapy
10.00 - 10.30	Dafydd Owen	The SGC-Pfizer Chemical Probes
10.30 - 11.00	<i>Coffee break</i>	
11.00 - 11.30	Robert Copeland	Tazemetostat: A Potent, Selective EZH2 Inhibitor as a Precision Cancer Therapeutic
11.30 - 12.00	Jian Jin	Discovery of Selective Inhibitors for PKMTs and PRMTs
12.00 - 12.30	Jorge DiMartino	Considerations for early clinical evaluation of epigenetic agents for cancer therapy
12.30 - 12.45	<i>Closing remarks and farewell</i>	

Evening event – Public outreach FRIAS Horizonte (in German)

Peter Spork